Assessment pending
RCT of immunotherapy plus senolytics versus control before head and neck cancer surgery
A Phase II randomised controlled trial evaluated tislelizumab (anti-PD-1 antibody) combined with dasatinib and quercetin (senolytics) as neoadjuvant therapy before surgery in patients with head and neck squamous cell carcinoma. The trial assessed efficacy and safety of this combined immunotherapy-senolytic approach.
OTHERRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 19, 2024 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Other
- Sample size
- —
- Duration
- —
- Population
- Patients with head and neck squamous cell carcinoma who are about to undergo surgery
- Primary outcome
- Efficacy and safety of the combination therapy (specific outcomes not specified)
- Effect size
- —
- Significance
- Not reported
- Journal
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Published
- Sep 19, 2024
Sources
Primary source
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.